table of content
1 Ulcerative Colitis Immunology Drugs Market Overview
1.1 Product Overview and Scope of Ulcerative Colitis Immunology Drugs
1.2 Ulcerative Colitis Immunology Drugs Segment by Type
1.2.1 Global Ulcerative Colitis Immunology Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Adalimumab
1.2.3 Certolizumab Pegol
1.2.4 Tofacitinib
1.2.5 Etanercept
1.2.6 Golimumab
1.2.7 Abatacept
1.2.8 Infliximab
1.2.9 Others
1.3 Ulcerative Colitis Immunology Drugs Segment by Application
1.3.1 Global Ulcerative Colitis Immunology Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Rheumatoid Arthritis
1.3.3 Crohn's Disease(CD)
1.3.4 Ankylosing Spondylitis(AS)
1.3.5 Psoriasis(Ps)
1.3.6 Ulcerative Colitis(UC)
1.4 Global Ulcerative Colitis Immunology Drugs Market Size Estimates and Forecasts
1.4.1 Global Ulcerative Colitis Immunology Drugs Revenue 2017-2028
1.4.2 Global Ulcerative Colitis Immunology Drugs Sales 2017-2028
1.4.3 Ulcerative Colitis Immunology Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Ulcerative Colitis Immunology Drugs Market Competition by Manufacturers
2.1 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Ulcerative Colitis Immunology Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Ulcerative Colitis Immunology Drugs Manufacturing Sites, Area Served, Product Type
2.5 Ulcerative Colitis Immunology Drugs Market Competitive Situation and Trends
2.5.1 Ulcerative Colitis Immunology Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Ulcerative Colitis Immunology Drugs Players Market Share by Revenue
2.5.3 Global Ulcerative Colitis Immunology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ulcerative Colitis Immunology Drugs Retrospective Market Scenario by Region
3.1 Global Ulcerative Colitis Immunology Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Ulcerative Colitis Immunology Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
3.3.1 North America Ulcerative Colitis Immunology Drugs Sales by Country
3.3.2 North America Ulcerative Colitis Immunology Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
3.4.1 Europe Ulcerative Colitis Immunology Drugs Sales by Country
3.4.2 Europe Ulcerative Colitis Immunology Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Ulcerative Colitis Immunology Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Region
3.5.2 Asia Pacific Ulcerative Colitis Immunology Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
3.6.1 Latin America Ulcerative Colitis Immunology Drugs Sales by Country
3.6.2 Latin America Ulcerative Colitis Immunology Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country
3.7.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Ulcerative Colitis Immunology Drugs Historic Market Analysis by Type
4.1 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2017-2022)
4.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Ulcerative Colitis Immunology Drugs Price by Type (2017-2022)
5 Global Ulcerative Colitis Immunology Drugs Historic Market Analysis by Application
5.1 Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2017-2022)
5.2 Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Ulcerative Colitis Immunology Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Janssen Biotech, Inc.
6.1.1 Janssen Biotech, Inc. Corporation Information
6.1.2 Janssen Biotech, Inc. Description and Business Overview
6.1.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
6.1.5 Janssen Biotech, Inc. Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 AbbVie Inc.
6.3.1 AbbVie Inc. Corporation Information
6.3.2 AbbVie Inc. Description and Business Overview
6.3.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
6.3.5 AbbVie Inc. Recent Developments/Updates
6.4 UCBCares
6.4.1 UCBCares Corporation Information
6.4.2 UCBCares Description and Business Overview
6.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio
6.4.5 UCBCares Recent Developments/Updates
6.5 AMGEN
6.5.1 AMGEN Corporation Information
6.5.2 AMGEN Description and Business Overview
6.5.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio
6.5.5 AMGEN Recent Developments/Updates
6.6 Celltrion Healthcare
6.6.1 Celltrion Healthcare Corporation Information
6.6.2 Celltrion Healthcare Description and Business Overview
6.6.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio
6.6.5 Celltrion Healthcare Recent Developments/Updates
6.7 Biogen
6.6.1 Biogen Corporation Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Biogen Ulcerative Colitis Immunology Drugs Product Portfolio
6.7.5 Biogen Recent Developments/Updates
6.8 Genentech USA, Inc.
6.8.1 Genentech USA, Inc. Corporation Information
6.8.2 Genentech USA, Inc. Description and Business Overview
6.8.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
6.8.5 Genentech USA, Inc. Recent Developments/Updates
6.9 ROCHE
6.9.1 ROCHE Corporation Information
6.9.2 ROCHE Description and Business Overview
6.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio
6.9.5 ROCHE Recent Developments/Updates
6.10 Pfizer Inc.
6.10.1 Pfizer Inc. Corporation Information
6.10.2 Pfizer Inc. Description and Business Overview
6.10.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
6.10.5 Pfizer Inc. Recent Developments/Updates
7 Ulcerative Colitis Immunology Drugs Manufacturing Cost Analysis
7.1 Ulcerative Colitis Immunology Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Ulcerative Colitis Immunology Drugs
7.4 Ulcerative Colitis Immunology Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Ulcerative Colitis Immunology Drugs Distributors List
8.3 Ulcerative Colitis Immunology Drugs Customers
9 Ulcerative Colitis Immunology Drugs Market Dynamics
9.1 Ulcerative Colitis Immunology Drugs Industry Trends
9.2 Ulcerative Colitis Immunology Drugs Market Drivers
9.3 Ulcerative Colitis Immunology Drugs Market Challenges
9.4 Ulcerative Colitis Immunology Drugs Market Restraints
10 Global Market Forecast
10.1 Ulcerative Colitis Immunology Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Ulcerative Colitis Immunology Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Ulcerative Colitis Immunology Drugs by Type (2023-2028)
10.2 Ulcerative Colitis Immunology Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Ulcerative Colitis Immunology Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Ulcerative Colitis Immunology Drugs by Application (2023-2028)
10.3 Ulcerative Colitis Immunology Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Ulcerative Colitis Immunology Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Ulcerative Colitis Immunology Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
